T-cell Epitope Prediction Using Quantitative MHC Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for identifying MHC binding peptides as T-cell epitopes are limited by providing only qualitative information, lacking quantitative measures of peptide stability, which is crucial for determining their effectiveness as immunogens.
Innovation Solution
A modified experimental protocol that assesses the stability of MHC-peptide complexes over time or under varying conditions, allowing for the identification of peptides with high stability scores that are likely to be effectively presented to T-cells, integrated into existing methods for improved T-cell epitope prediction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current pMHC stability assays are used to evaluate peptide stability, then stability information can be obtained, but the assays are biased and suffer experimental limitations in scale
Solution Approach 1:
The patent replaces traditional mechanical/wet-lab pMHC stability assays with an in silico computational prediction system. The method uses algorithms to predict peptide stability based on amino acid sequence and MHC molecule characteristics, eliminating the need for complex experimental assays while providing scalable predictions for numerous peptides simultaneously.
Solution Approach 2:
The patent creates a computational model that replicates the function of experimental pMHC stability assays. By developing an in silico prediction system that mimics the behavior and output of wet-lab assays, the method provides stable peptide identification without requiring physical experimentation, thus resolving the scale and complexity limitations.
2Reliability
If prediction algorithms are trained on selected pMHC stability data, then T-cell epitope prediction can be performed, but the algorithms have not demonstrated impressive results when benchmarked against pMHC affinity predictors
Solution Approach 1:
The patent changes the approach from using experimental stability data to using in silico predicted stability data. By modifying the data source and prediction methodology, the system achieves improved T-cell epitope prediction accuracy compared to algorithms trained on traditional stability assays, while maintaining computational efficiency.
Solution Approach 2:
The patent introduces an in silico prediction model as an intermediary between peptide sequence and stability assessment. This computational mediator translates amino acid sequences into stability predictions without requiring direct experimental measurement, enabling more reliable and scalable epitope identification.
3Ease of operation
If only qualitative information from current methods is used, then identification of MHC binding peptides is simple, but quantitative measures of peptide stability are lacking which are crucial for determining effectiveness as immunogens
Solution Approach 1:
The patent merges the simplicity of in silico prediction with the quantitative information capability of stability assessment. By combining computational ease with detailed stability scoring, the method provides both user-friendly operation and comprehensive quantitative data on peptide-MHC complex stability, eliminating the need to choose between simplicity and information richness.
Data Source
AI summary
A method for T-cell epitope prediction where quantitative scores of stability in the binding between peptides and MHC molecules are integrated into the derivation of the likelihood that a peptide of defined amino acid sequence constitutes a T-cell epitope. Preferably, stability data are obtained an MS-based method for identification of MHC binding peptides, where the binding capability is quantitatively assessed to allow distinction between stably binding peptides and peptides that are unlikely to be presented to T-cells. The method includes a step of time-course or thermostability testing of naturally processed peptides bound to MHC. Also disclosed are methods for preparation of personalized immunogenic compositions, methods of therapeutic treatment of malignancies, and a computer system that implements the T-cell epitope prediction method.